Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women

Osteoporosis International

Volumn 23, Issue 2, 2012, Pages 695-703

  Osaki, M ^a   Tatsuki, K ^b   Hashikawa, T ^a   Norimatsu, T ^a   Chiba, K ^a   Motokawa, S ^c   Furuichi, I ^d   Doiguchi, Y ^e   Aoyagi, K ^a   Shindo, H ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^d Ureshino Medical Center   (Japan)

^e NAGASAKI ROSAI HOSPITAL   (Japan)

Author keywords

Bisphosphonate; Hip fracture; Matched cohort study; Osteoporosis; Risedronate

Indexed keywords

RISEDRONIC ACID;

AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; HAZARD RATIO; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; INCIDENCE; JAPANESE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE;

AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; EPIDEMIOLOGIC METHODS; ETIDRONIC ACID; FEMALE; HIP FRACTURES; HUMANS; LUMBAR VERTEBRAE; MEDICATION ADHERENCE; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; RECURRENCE; TREATMENT OUTCOME;

EID: 84857365220     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1556-7     Document Type: Article

References (27)

1. Osteoporosis Prevention, Diagnosis, and Therapy. NIH Consensus Statement 2000 March 27-29; 17: 1-45
2. JA Kanis EV McCloskey H Johansson, et al. 2008 A reference standard for the description of osteoporosis Bone 42 467 475 18180210 10.1016/j.bone.2007.11. 001 1:CAS:528:DC%2BD1cXitVOmtbk%3D
3. AC Looker LJ Melton TB Harris, et al. 2009 Prevalence and trends in low femur bone density among older US adults: NHANES 2005-2006 compared with NHANES III J Bone Miner Res 25 1 64 7 10.1359/jbmr.090706
4. Guidelines for prevention and treatment of osteoporosis. (2006) ed. Life Science Publishing Co., Ltd
5. C Cooper G Campion LJ Melton 3rd 1992 Hip fractures in the elderly: a world-wide projection Osteoporos Int 2 285 289 1421796 10.1007/BF01623184 1:STN:280:DyaK3s%2Fktlyrtw%3D%3D
6. B Gullberg O Johnell JA Kanis 1997 World-wide projections for hip fracture Osteoporos Int 7 407 413 9425497 10.1007/PL00004148 1:STN:280:DyaK1c%2Fos1Kgtg%3D%3D
7. H Orimo Y Yaegashi T Onoda 2009 Hip fracture incidence in Japan: estimates of new patients in 2007 and 20-year trends Arch Osteoporos 4 71 77 20234789 10.1007/s11657-009-0031-y
8. Prevention and management of osteoporosis. Report of a WHO scientific group. WHO Technical Report Series 921, 2003
9. P Geusens M McClung 2001 Review of risedronate in the treatment of osteoporosis Expert Opin Pharmacother 2 2011 2025 11825332 10.1517/14656566.2. 12.2011 1:CAS:528:DC%2BD38XhslCjtA%3D%3D
10. I Fogelman C Ribot R Smith, et al. 2000 Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group J Clin Endocrinol Metab 85 1895 1900 10843171 10.1210/jc.85.5.1895 1:CAS:528:DC%2BD3cXlt1Wlsb4%3D
11. M Fukunaga K Kushida H Kishimoto, et al. 2002 A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial Osteoporos Int 13 971 979 12459940 10.1007/s001980200135 1:CAS:528:DC%2BD38XptFGitrY%3D
12. ST Harris NB Watts HK Genant, et al. 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial Vertebral Efficacy With Risedronate Therapy (VERT) study group JAMA 282 14 1344 1352 10527181 10.1001/jama.282.14. 1344 1:CAS:528:DyaK1MXmvFansr0%3D
13. J Reginster HW Minne OH Sorensen, et al. 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) study group Osteoporos Int 11 83 91 10663363 10.1007/s001980050010 1:CAS:528:DC%2BD3cXhvFGgsr0%3D
14. MR McClung P Geusens PD Miller, et al. 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group N Engl J Med 344 333 340 11172164 10.1056/NEJM200102013440503 1:CAS:528: DC%2BD3MXht1Wlu7g%3D
15. T Masud M McClung P Geusens 2009 Reducing hip fracture risk with risedronate in elderly women with established osteoporosis Clin Interv Aging 4 445 449 19966913 10.2147/CIA.S8200 1:CAS:528:DC%2BD1MXhsVOgu7nK
16. C MacLean S Newberry M Maglione, et al. 2008 Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis Ann Intern Med 148 197 213 18087050
17. S Yoshihiro K Tomohiro S Kei, et al. 2005 The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease Arch Inter Med 165 1737 1742 10.1001/archinte.165. 15.1737
18. S Yoshihiro I Jun K Tomohiro, et al. 2005 Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke Arch Inter Med 165 1743 1748 10.1001/archinte.165.15.1743
19. Investigational Committee for Osteoporosis Diagnosis Standard Japanese Society for Bone and Mineral Research 2001 Diagnosis standard for primary osteoporosis (2000 revised edition) J Jpn Soc Bone Miner Res 8 76 82
20. C De Laet JA Kanis A Odén, et al. 2005 Body mass index as a predictor of fracture risk: a meta-analysis Osteoporos Int 16 1330 1338 15928804 10.1007/s00198-005-1863-y
21. T Chevalley E Guilley FR Herrmann, et al. 2007 Incidence of hip fracture over a 10-year period (1991-2000): reversal of a secular trend Bone 40 1284 1289 17292683 10.1016/j.bone.2006.12.063 1:STN:280:DC%2BD2s3itFWgsA%3D%3D
22. LJ Melton 3rd AE Kearns EJ Atkinson 2009 Secular trends in hip fracture incidence and recurrence Osteoporos Int 20 687 694 18797813 10.1007/s00198-008- 0742-8
23. H Hagino K Furukawa S Fujiwara, et al. 2009 Recent trends in the incidence and lifetime risk of hip fracture in Tottori, Japan Osteoporos Int 20 543 548 18633667 10.1007/s00198-008-0685-0 1:STN:280:DC%2BD1M7osVClsg%3D%3D
24. KW Lyles CS Colón-Emeric JS Magaziner, et al. 2007 Zoledronic acid and clinical fractures and mortality after hip fracture N Engl J Med 357 1799 1809 17878149 10.1056/NEJMoa074941 1:CAS:528:DC%2BD2sXht1Kit7nN
25. CP Peter MV Kindt JA Majka 1998 Comparative study of potential for bisphosphonates to damage gastric mucosa of rats Dig Dis Sci 43 1009 1015 9590415 10.1023/A:1018826600877 1:CAS:528:DyaK1cXjsVWiurw%3D
26. K Kushida H Kishimoto, et al. 2002 Efficacy and safety of long-term treatment with risedronate in patients with osteoporosis and osteopenia Osteoporos Jpn 10 85 97 in Japanese
27. FH Hooven JD Adachi S Adami, et al. 2009 The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design Osteoporos Int 20 1107 1116 19468663 10.1007/s00198-009-0958-2 1:STN:280:DC%2BD1MzptFyntw%3D%3D